Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains
- PMID: 37930069
- DOI: 10.1097/QCO.0000000000000977
Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains
Abstract
Purpose of review: This article aims to review the epidemiology of nonfermenting Gram-negative bacilli (NFGNB) based on recent literature reports, particularly, of the less common, but with emerging clinical significance species.
Recent findings: The reported frequency of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa is increasing, with very significant variability, however, between different countries. Apart from the major NFGNB, that is, A. baumannii and P. aeruginosa, already recognized as of critical importance healthcare risks, several other NFGNB genera have been increasingly associated with diverse severe infections, such as Stenotrophomonas maltophilia, Burkholderia spp., Elizabethkingia spp., Chryseobacterium spp., Achromobacter spp., Alcaligenes spp., Sphingomonas spp., Shewanella spp. and Ralstonia spp., among others.
Summary: The exploration of the epidemiology, as well as the pathogenic potential of the of the less frequent, but emerging and increasingly reported NFGNB, is crucial, not only for immunocompromised patients, but also for critically ill patients without overt immunosuppression. As we are heading fast towards a postantibiotic era, such information would contribute to the optimal antimicrobial management, that is, providing prompt, appropriate antimicrobial coverage when needed and, at the same time, avoiding overuse and/or inappropriate use of antimicrobial therapy. Also, it would help to better understand their transmission dynamics and to develop effective prevention strategies.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center.J Microbiol Immunol Infect. 2019 Apr;52(2):304-311. doi: 10.1016/j.jmii.2018.06.007. Epub 2018 Jul 17. J Microbiol Immunol Infect. 2019. PMID: 30097388
-
Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.Am J Med. 2006 Jun;119(6 Suppl 1):S29-36; discussion S62-70. doi: 10.1016/j.amjmed.2006.03.014. Am J Med. 2006. PMID: 16735148 Review.
-
Emergence of unusual nonfermenting Gram-negative nosocomial pathogens in a Saudi hospital.Jpn J Infect Dis. 2013;66(6):507-11. doi: 10.7883/yoken.66.507. Jpn J Infect Dis. 2013. PMID: 24270139
-
In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.Microb Drug Resist. 2012 Aug;18(4):396-401. doi: 10.1089/mdr.2011.0195. Epub 2012 Feb 15. Microb Drug Resist. 2012. PMID: 22335615
-
An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.Pharmacotherapy. 2020 Sep;40(9):936-951. doi: 10.1002/phar.2447. Epub 2020 Aug 14. Pharmacotherapy. 2020. PMID: 32687670 Review.
Cited by
-
Stenotrophomonas maltophilia: The Landscape in Critically Ill Patients and Optimising Management Approaches.Antibiotics (Basel). 2024 Jun 22;13(7):577. doi: 10.3390/antibiotics13070577. Antibiotics (Basel). 2024. PMID: 39061259 Free PMC article. Review.
-
Correlation between Stenotrophomonas maltophilia incidence and systemic antibiotic use: A 10-year retrospective, observational study in Hungary.Eur J Microbiol Immunol (Bp). 2024 Mar 5;14(2):185-194. doi: 10.1556/1886.2024.00022. Print 2024 May 14. Eur J Microbiol Immunol (Bp). 2024. PMID: 38441614 Free PMC article.
-
At the Intersection of Critical Care and Infectious Diseases: The Year in Review.Biomedicines. 2024 Mar 2;12(3):562. doi: 10.3390/biomedicines12030562. Biomedicines. 2024. PMID: 38540175 Free PMC article. Review.
-
Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.Infect Dis Ther. 2025 May;14(5):1027-1042. doi: 10.1007/s40121-025-01126-1. Epub 2025 Apr 2. Infect Dis Ther. 2025. PMID: 40172794 Free PMC article.
-
Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes.Antibiotics (Basel). 2024 Feb 8;13(2):169. doi: 10.3390/antibiotics13020169. Antibiotics (Basel). 2024. PMID: 38391555 Free PMC article.
References
-
- WHO. Prioritization of pathogens to guide discovery, research, and development of new antibiotics for drug resistant bacterial infections, including tuberculosis. Essent Med Health Products. 2017 (accessed 9 June 2023).
-
- Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines (Basel) 2021; 9:570.
-
- Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32:e00031–19.
-
- https://globalsmartsite.com/#/heatmaps (accessed 8 June 2023).
-
- https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobi... (accessed 19 July 2023).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous